Adapthealth Corp
$ 5.69
-5.87%
07 Aug - close price
- Market Cap 759,098,000 USD
- Current Price $ 5.69
- High / Low $ 6.07 / 5.66
- Stock P/E N/A
- Book Value 10.34
- EPS -1.61
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.15 %
- 52 Week High 13.43
- 52 Week Low 5.67
About
AdaptHealth Corp. The company is headquartered in Plymouth Meeting, Pennsylvania.
Analyst Target Price
$9.86
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-05 | 2026-02-24 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-25 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-07 |
| Reported EPS | 0.03 | -0.05 | 0.2689 | 0.23 | 0.07 | 0.02 | 0.4194 | 0.22 | 0.22 | 0.15 | -1.91 | 0.21 |
| Estimated EPS | -0.01 | 0.01 | 0.3604 | 0.24 | 0.16 | 0.04 | 0.281 | 0.18 | 0.19 | 0.06 | 0.18 | 0.2 |
| Surprise | 0.04 | -0.06 | -0.0915 | -0.01 | -0.09 | -0.02 | 0.1384 | 0.04 | 0.03 | 0.09 | -2.09 | 0.01 |
| Surprise Percentage | 400% | -600% | -25.3885% | -4.1667% | -56.25% | -50% | 49.2527% | 22.2222% | 15.7895% | 150% | -1161.1111% | 5% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AHCO
2026-08-06 13:40:13
SueWallSt, powered by Levi & Korsinsky LLP, has launched an investigation into AdaptHealth Corp. (AHCO) after the company drastically lowered its full-year 2026 revenue guidance, causing a significant stock price drop. The investigation focuses on whether AdaptHealth made misleading statements regarding its financial outlook, particularly after CFO Jason Clemens raised initial guidance but later reset it due to undisclosed factors. Investors who suffered losses after purchasing AHCO shares are encouraged to contact SueWallSt for a free case evaluation.
2026-08-05 19:20:06
The Law Offices of Frank R. Cruz has announced a securities fraud investigation into AdaptHealth Corp. (AHCO) following a significant drop in its stock price. This investigation comes after AdaptHealth reported a substantial earnings miss and cut its full-year 2026 adjusted EBITDA guidance, citing issues with its West Coast Capitated Contract and unexpected price increases. Shareholders who lost money are urged to contact the law firm to learn about potentially pursuing a claim.
2026-08-05 18:20:06
Levi & Korsinsky is investigating AdaptHealth Corp. (AHCO) after the company significantly cut its full-year 2026 adjusted EBITDA guidance. The reduction from an initial range of $680 million-$730 million to approximately $490 million-$520 million, a drop of $190 million-$210 million, caused a stock decline of up to 26%. The investigation focuses on whether the company made misleading statements regarding its financial outlook and the normalization of labor costs prior to this guidance revision.
2026-08-05 17:20:06
This article highlights several stocks that experienced significant movement yesterday, August 4, 2026, due to their second-quarter earnings reports. AdaptHealth and UL Solutions saw declines after reporting disappointing results, while Ball's strong earnings were overshadowed by profitability concerns. In contrast, Tidewater and Wayfair both saw their stock prices rise following positive investor reactions to their respective quarterly performances.
2026-08-05 11:41:12
AdaptHealth Corp. published its Q2 2026 earnings call presentation on August 5, 2026. The company reported an EPS of -$0.07, missing estimates by $0.23, and revenue of $740.31M, down 7.50% year-over-year and missing estimates by $106.47M. This information was shared in conjunction with their earnings call.
2026-08-04 23:40:13
AdaptHealth Corp. announced its second-quarter 2026 financial results, revealing a definitive agreement to sell its Diabetes Health business for $235 million in cash. This divestiture is part of AdaptHealth's strategy to focus on its core Sleep Health, Respiratory Health, and Wellness-at-Home segments. The company also revised its full-year 2026 financial guidance, lowering its Adjusted EBITDA forecast to $490 million to $520 million due to the sale, impacts from a capitated agreement, and manufacturer price increases.
